share_log

Jefferies Initiates Coverage On ImmunityBio with Buy Rating, Announces Price Target of $8

Jefferies Initiates Coverage On ImmunityBio with Buy Rating, Announces Price Target of $8

傑富瑞集團以買入評級啓動對ImmunityBio的報道,宣佈目標股價爲8美元
Benzinga Real-time News ·  2022/08/03 07:18

Jefferies analyst Kelly Shi initiates coverage on ImmunityBio (NASDAQ:IBRX) with a Buy rating and announces Price Target of $8.

傑富瑞分析師Kelly Shih以買入評級啟動免疫生物(納斯達克:IBRX)的報道,並宣佈目標價為8美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論